Pimecrolimus Cream 1%: A Potential New Treatment for Chronic Hand Dermatitis

Donald V. Belsito, Joseph F. Fowler, James G. Marks, David M. Pariser, Jon Hanifin, Ida Alzira Gomes Duarte, Mario C. Pires, Ponciano D. Cruz, Richard G.B. Langley, Premal Patel, Christopher Bush, Mark Thurston, Michael Graeber, Robert Cherill

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


A multicenter, randomized, vehicle-controlled, 3-week study was conducted in patients with chronic hand dermatitis (HD) of various etiologies and locations to identify subgroups particularly responsive to twice-daily application of pimecrolimus cream 1% with overnight occlusion. A total of 294 patients were randomized to the study. By the final visit on day 22, there was a trend toward greater clearance in patients who received pimecrolimus than in those treated with vehicle cream. An analysis of treatment success by various stratification factors was performed, and it was found that palmar involvement had notable impact on response (P = .033). Patients in the pimecrolimus group continued to improve throughout the study; however, in the vehicle group, improvement plateaued after 15 days. Pimecrolimus was well tolerated, with a low rate of application-site reactions such as burning. Pimecrolimus cream 1%, when used twice daily with overnight occlusion, may be of benefit in the management of chronic HD.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
Issue number1
StatePublished - Jan 2004

All Science Journal Classification (ASJC) codes

  • Dermatology


Dive into the research topics of 'Pimecrolimus Cream 1%: A Potential New Treatment for Chronic Hand Dermatitis'. Together they form a unique fingerprint.

Cite this